Zuranolone is an investigational drug that showed evidence in the phase 3 SKYLARK study for the treatment of postpartum depression (PPD). The SKYLARK research, including a total of 300 women, was a diverse study, in which 22% African American women, and 38% Hispanic or Latina women were considered. Zuranolone dosed at 50 mg was given once for 14 days, including placebo, and the drug demonstrated incredible results with meaningful improvement in the symptoms of depression. Katherine Dawson, MD, head of the Therapeutics Development Unit at Biogen was hopeful after the results and said that they can offer an innovative solution to women suffering from overwhelming depression.
Read More from Psychiatric Times
English